Cencora, Inc.

The filings describe a larger, more acquisition-dependent company. Fiscal 2025 revenue was $321.33 billion, up from $293.96 billion in fiscal 2024, a year-over-year increase of about 9.3%. The six-month results show revenue growing 4.7%, gross profit growing 18.6%, and total operating expenses growing faster, at 22.8%, an increase of $882.0 million. That gap matters because the MD&A attributes much of the expense growth to the RCA and OneOncology acquisitions, and it also cites an impairment of assets in the U.S. Consulting Services business that is classified as held for sale. Segment operating income rose 8.6%, a smaller gain than gross profit. The February 2, 2026 OneOncology transaction had total fair value consideration of $7,387.1 million, including $4,648.7 million in cash, $1,934.2 million for the previously held equity method stake, and $752.1 million of estimated contingent consideration tied to physicians and management who kept an 8% interest. Funding came from new debt and cash on hand, and readers may want to look at Note 7 for the debt terms. The RCA acquisition, completed January 2, 2025, also carried $393.1 million of contingent consideration tied to fiscal 2027 and 2028 objectives, so future payments are part of the cost picture. The 10-K also describes a reorganized reporting structure in which the Other category, including MWI Animal Health, Profarma and U.S. Consulting Services, is exploring strategic alternatives. Management says no key contracts expire in the next twelve months, but the risk factors name generic drug expansion, brand-to-generic conversion rates, pricing changes and reimbursement pressure as ongoing factors affecting revenue. Effective tax rates were 21.5% for the six months ended March 31, 2026, compared with 21.8% a year earlier. Taken together, the filings show strong top-line and gross profit growth, with acquisitions, one-time or volatile accounting items and contingent payments making the underlying trend harder to read.

Catalyst.Growth in the six months ended March 31, 2026 came from both reportable segments and from acquisitions. Revenue rose $7.3 billion, or 4.7%, to $164.3 billion. U.S. Healthcare Solutions revenue grew 4.0%, which management attributes mainly to unit volume growth, including specialty products and GLP-1 class products, whose sales rose $2.9 billion, or 16.7%. International Healthcare Solutions revenue rose 11.2%, driven mainly by its European distribution business. Gross profit increased $1,042.6 million, or 18.6%, to $6.66 billion. Management credited the February 2, 2026 acquisition of OneOncology and the January 2025 acquisition of RCA for part of the U.S. segment's profit growth.

Hidden risk.Part of the gross profit gain came from items that can swing sharply from period to period. LIFO credits were $287.6 million in the six months ended March 31, 2026, compared with LIFO expense of $32.1 million a year earlier, a swing of about $319.7 million. Gains from antitrust litigation settlements fell from $221.5 million to $28.7 million. The MD&A also lists the loss of an oncology customer and a grocery customer, plus lower sales to a large mail order customer due to brand conversions, as offsets to growth. Risk factors state that customer contracts may expire or be renewed on less favorable terms, which could reduce revenue, results and cash flows.